PortalPublikationenDelayed Imaging Improves Lesion Detectability in [99mTc]Tc-P...

Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer

Standard

Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer. / Berliner, Christoph; Steinhelfer, Lisa; Chantadisai, Maythinee; Kroenke, Markus; Koehler, Daniel; Pose, Randi; Bannas, Peter; Knipper, Sophie; Eiber, Matthias; Maurer, Tobias.

in: J NUCL MED, Jahrgang 64, Nr. 7, 07.2023, S. 1036-1042.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Berliner, C, Steinhelfer, L, Chantadisai, M, Kroenke, M, Koehler, D, Pose, R, Bannas, P, Knipper, S, Eiber, M & Maurer, T 2023, 'Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer', J NUCL MED, Jg. 64, Nr. 7, S. 1036-1042. https://doi.org/10.2967/jnumed.122.265252

APA

Berliner, C., Steinhelfer, L., Chantadisai, M., Kroenke, M., Koehler, D., Pose, R., Bannas, P., Knipper, S., Eiber, M., & Maurer, T. (2023). Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer. J NUCL MED, 64(7), 1036-1042. https://doi.org/10.2967/jnumed.122.265252

Vancouver

Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R et al. Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer. J NUCL MED. 2023 Jul;64(7):1036-1042. https://doi.org/10.2967/jnumed.122.265252

Bibtex

@article{b462b81342bb405da3d135f67c267160,
title = "Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer",
abstract = "Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [99mTc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. Methods: We retrospectively analyzed 222 patients selected for radioguided surgery using [99mTc]Tc-PSMA-I&S SPECT/CT at different time points after injection (≤4 h and >15 h). In total, 386 prostate-specific membrane antigen (PSMA) PET predetermined lesions were analyzed on SPECT/CT using a 4-point scale, and the results were compared between early and late imaging groups, with uni- and multivariate analyses performed including prostate-specific antigen, injected [99mTc]Tc-PSMA-I&S activity, Gleason grade group, initial TNM stage, and, stratified by size, PSMA PET/CT-positive lymph nodes. PSMA PET/CT findings served as the standard of reference. Results: [99mTc]Tc-PSMA-I&S SPECT/CT had a significantly higher positivity rate for detecting lesions in the late than the early imaging group (79%, n = 140/178, vs. 27%, n = 12/44 [P < 0.05] on a patient basis; 60%, n = 195/324, vs. 21%, n = 13/62 [P < 0.05] on a lesion basis). Similar positivity rates were found when lesions were stratified by size. Multivariate analysis found that SUVmax on PSMA PET/CT and the uptake time of [99mTc]Tc-PSMA-I&S were independent predictors for lesion detectability on SPECT/CT. Conclusion: Late imaging (>15 h after injection) should be preferred when [99mTc]Tc-PSMA-I&S SPECT/CT is used for lesion detection in early biochemical recurrence of prostate cancer. However, the performance of PSMA SPECT/CT is clearly inferior to that of PSMA PET/CT.",
keywords = "Male, Humans, Prostate/pathology, Positron Emission Tomography Computed Tomography/methods, Retrospective Studies, Neoplasm Recurrence, Local, Prostatic Neoplasms/pathology, Single Photon Emission Computed Tomography Computed Tomography, Gallium Radioisotopes",
author = "Christoph Berliner and Lisa Steinhelfer and Maythinee Chantadisai and Markus Kroenke and Daniel Koehler and Randi Pose and Peter Bannas and Sophie Knipper and Matthias Eiber and Tobias Maurer",
note = "{\textcopyright} 2023 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2023",
month = jul,
doi = "10.2967/jnumed.122.265252",
language = "English",
volume = "64",
pages = "1036--1042",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer

AU - Berliner, Christoph

AU - Steinhelfer, Lisa

AU - Chantadisai, Maythinee

AU - Kroenke, Markus

AU - Koehler, Daniel

AU - Pose, Randi

AU - Bannas, Peter

AU - Knipper, Sophie

AU - Eiber, Matthias

AU - Maurer, Tobias

N1 - © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2023/7

Y1 - 2023/7

N2 - Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [99mTc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. Methods: We retrospectively analyzed 222 patients selected for radioguided surgery using [99mTc]Tc-PSMA-I&S SPECT/CT at different time points after injection (≤4 h and >15 h). In total, 386 prostate-specific membrane antigen (PSMA) PET predetermined lesions were analyzed on SPECT/CT using a 4-point scale, and the results were compared between early and late imaging groups, with uni- and multivariate analyses performed including prostate-specific antigen, injected [99mTc]Tc-PSMA-I&S activity, Gleason grade group, initial TNM stage, and, stratified by size, PSMA PET/CT-positive lymph nodes. PSMA PET/CT findings served as the standard of reference. Results: [99mTc]Tc-PSMA-I&S SPECT/CT had a significantly higher positivity rate for detecting lesions in the late than the early imaging group (79%, n = 140/178, vs. 27%, n = 12/44 [P < 0.05] on a patient basis; 60%, n = 195/324, vs. 21%, n = 13/62 [P < 0.05] on a lesion basis). Similar positivity rates were found when lesions were stratified by size. Multivariate analysis found that SUVmax on PSMA PET/CT and the uptake time of [99mTc]Tc-PSMA-I&S were independent predictors for lesion detectability on SPECT/CT. Conclusion: Late imaging (>15 h after injection) should be preferred when [99mTc]Tc-PSMA-I&S SPECT/CT is used for lesion detection in early biochemical recurrence of prostate cancer. However, the performance of PSMA SPECT/CT is clearly inferior to that of PSMA PET/CT.

AB - Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [99mTc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. Methods: We retrospectively analyzed 222 patients selected for radioguided surgery using [99mTc]Tc-PSMA-I&S SPECT/CT at different time points after injection (≤4 h and >15 h). In total, 386 prostate-specific membrane antigen (PSMA) PET predetermined lesions were analyzed on SPECT/CT using a 4-point scale, and the results were compared between early and late imaging groups, with uni- and multivariate analyses performed including prostate-specific antigen, injected [99mTc]Tc-PSMA-I&S activity, Gleason grade group, initial TNM stage, and, stratified by size, PSMA PET/CT-positive lymph nodes. PSMA PET/CT findings served as the standard of reference. Results: [99mTc]Tc-PSMA-I&S SPECT/CT had a significantly higher positivity rate for detecting lesions in the late than the early imaging group (79%, n = 140/178, vs. 27%, n = 12/44 [P < 0.05] on a patient basis; 60%, n = 195/324, vs. 21%, n = 13/62 [P < 0.05] on a lesion basis). Similar positivity rates were found when lesions were stratified by size. Multivariate analysis found that SUVmax on PSMA PET/CT and the uptake time of [99mTc]Tc-PSMA-I&S were independent predictors for lesion detectability on SPECT/CT. Conclusion: Late imaging (>15 h after injection) should be preferred when [99mTc]Tc-PSMA-I&S SPECT/CT is used for lesion detection in early biochemical recurrence of prostate cancer. However, the performance of PSMA SPECT/CT is clearly inferior to that of PSMA PET/CT.

KW - Male

KW - Humans

KW - Prostate/pathology

KW - Positron Emission Tomography Computed Tomography/methods

KW - Retrospective Studies

KW - Neoplasm Recurrence, Local

KW - Prostatic Neoplasms/pathology

KW - Single Photon Emission Computed Tomography Computed Tomography

KW - Gallium Radioisotopes

U2 - 10.2967/jnumed.122.265252

DO - 10.2967/jnumed.122.265252

M3 - SCORING: Journal article

C2 - 37230531

VL - 64

SP - 1036

EP - 1042

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 7

ER -